Mark Stewart, MD
Interventional Pain Medicine · Augusta, GANPI 1225114051
Payments from drug & device makers
Across 164 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$482
- Scilex Pharmaceuticals Inc.$448
- IBSA Pharma Inc.$296
- Collegium Pharmaceutical, Inc.$242
- Medtronic$207
- Arbor Pharmaceuticals, Inc.$165
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,19197%
- Education$1033%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $482 |
| Scilex Pharmaceuticals Inc. | 22 | $448 |
| IBSA Pharma Inc. | 15 | $296 |
| Collegium Pharmaceutical, Inc. | 12 | $242 |
| Medtronic(2 entities) | 14 | $207 |
| Arbor Pharmaceuticals, Inc. | 12 | $165 |
| Forte Bio-pharma LLC | 2 | $164 |
| Nevro Corp. | 6 | $162 |
| Biodelivery Sciences International, Inc. | 7 | $124 |
| Lemaitre Vascular, Inc. | 1 | $110 |
| Amgen(2 entities) | 7 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| Azurity Pharmaceuticals, Inc. | 6 | $90 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Lilly USA, LLC | 4 | $55 |
| Abbott | 3 | $50 |
| Biotronik NRO, Inc. | 2 | $38 |
| Pfizer | 2 | $35 |
| Avanos Medical | 2 | $29 |
| Bioventus LLC | 1 | $25 |
| Masimo Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Averitas Pharma Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Spinal Simplicity, LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Merz North America, Inc. | 1 | $17 |
| Stimwave Technologies Incorporated | 1 | $16 |
| Protega Pharmaceutials Inc | 1 | $16 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$561
- Nalocet$140
- ANASTOCLIP$110
How this compares
$3,293 in reported general payments places this provider in the 40th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,266 | $74,991 |
| PercocetOxycodone Hcl/Acetaminophen | 12 | $51,783 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,625 | $38,111 |
| Xtampza ErOxycodone Myristate | 118 | $29,962 |
| Hysingla ErHydrocodone Bitartrate | 57 | $25,282 |
| OxycontinOxycodone Hcl | 80 | $23,108 |
| Oxycodone Hcl | 1,376 | $20,555 |
| Buprenorphine | 84 | $17,737 |
| Pregabalin | 909 | $16,120 |
| HorizantGabapentin Enacarbil | 21 | $12,862 |
| ZtlidoLidocaine | 20 | $12,421 |
| LyricaPregabalin | 11 | $10,181 |
| Morphine Sulfate ErMorphine Sulfate | 584 | $9,227 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,586 |
| Nucynta ErTapentadol Hcl | 16 | $8,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $242 | $38,340134 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $21 | $22,623296 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $165 | $12,86221 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $448 | $12,42120 claims |
| PfizerLyrica | $35 | $10,18111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Augusta
- Richard EpterAugusta$31K
- Shalin ShahAugusta$6K
- Marvin TarkMarietta$3.6M
- Jordan TateJasper$764K
- Emmanuel GageBrunswick$648K
- Christopher BovinetBrunswick$356K
- D Terrence FosterStockbridge$305K
- David RosenfeldCovington$287K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.